Navigation and service

BIENNIAL REPORT 2019/2020

Welcome

Welcome

Research

Research

International

International

Regulation

Regulation

Organisation

Organisation

Data & Facts

Data & Facts

05.10.2020 back forward

Start of Two Rolling Review Procedures

Document evaluation (Source: Aymanejed / Pixabay)

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) initiates two rolling review procedures for COVID-19 vaccines. The aim of the rolling review, in which the required data is submitted and evaluated successively, is to accelerate the marketing authorisation procedure. The requirements on the quality, safety and efficacy of the medicinal products nonetheless remain high. The rolling review procedure for the vector vaccine from AstraZeneca starts on 5 October 2020, followed on 6 October 2020 by the rolling review for the mRNA vaccine from BioNTech.